Expert Insights

Sponsored

Videos

Part 1: Highlights–Importance of Biomarker Testing

10/27/2022

Four distinguished oncologists – Drs Corey Langer, Aaron Lisberg, Lyudmila Bazhenova, and Misako Nagasaka – describe biomarker testing in patients with advanced/metastatic NSCLC treated at their institutions. Topics include their use of...

Four distinguished oncologists –...

10/27/2022

Oncology

Videos

Novel CELMoD Agents for Multiple Myeloma: Iberdomide and Mezigdomide

10/21/2022

Paul Richardson, MD, provides an update on the treatment of multiple myeloma with novel CELMoD agents iberdomide and mezigdomide at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.

Paul Richardson, MD, provides an...

10/21/2022

Oncology

Videos

Outpatient Combination Therapy in Patients With Newly Diagnosed AML

10/21/2022

Keith Pratz, MD, provides insights into navigating outpatient combination therapy in newly diagnosed acute myeloid leukemia at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.

Keith Pratz, MD, provides...

10/21/2022

Oncology

Videos

Treatment for Advanced and Recurrent Endometrial Cancer

10/20/2022

BJ Rimel, MD, shares important considerations for clinicians when caring for patients with advanced and recurrent endometrial cancer, a topic she presented at the 2022 GDU Women’s Oncology virtual meeting.

BJ Rimel, MD, shares important...

10/20/2022

Oncology

Videos

Emerging Opportunities for the Treatment of Cervical Cancer

10/20/2022

Ritu Salani, MD, reviews new and upcoming opportunities for the treatment of patients with cervical cancer, a topic she presented at the 2022 GDU Women’s Oncology virtual meeting.

Ritu Salani, MD, reviews new and...

10/20/2022

Oncology

Videos

Novel Agents for Managing Patients With Relapsed ALL

10/19/2022

Michal Bar-Natan, MD, provides an update on the newest agents for management of relapsed ALL at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.

Michal Bar-Natan, MD, provides...

10/19/2022

Oncology

Videos

Current and Future Treatment Paradigms in Second-Line Endometrial Cancer

10/19/2022

BJ Rimel, MD, shares new and upcoming treatments in the second-line setting for patients with endometrial cancer, a topic she presented at the 2022 GDU Women’s Oncology virtual meeting.

BJ Rimel, MD, shares new and...

10/19/2022

Oncology

Videos

Considerations When Treating Premenopausal Patients With Breast Cancer

10/19/2022

Matteo Lambertini, MD, PhD, discusses insights, strategies, and potential complications when treating a younger patient with breast cancer, a topic he presented at the 2022 GDU Women’s Oncology virtual meeting.

Matteo Lambertini, MD, PhD,...

10/19/2022

Oncology

Elias Jabbour, MD, MD Anderson Cancer Center

Videos

Incorporation of Antibodies Into the Management of Upfront and Relapsed ALL

10/19/2022

Elias Jabbour, MD, provides an update on the incorporation of antibodies into the management of upfront and relapsed ALL.

Elias Jabbour, MD, provides an...

10/19/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology